N/A
Manufactured by Lundbeck Pharmaceuticals LLC
19,478 FDA adverse event reports analyzed
Last updated: 2026-04-14
VIGABATRIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Lundbeck Pharmaceuticals LLC. The most commonly reported adverse reactions for VIGABATRIN include SEIZURE, DRUG INEFFECTIVE, DRUG DOSE OMISSION, DEATH, SOMNOLENCE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VIGABATRIN.
Out of 14,065 classified reports for VIGABATRIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 19,478 FDA FAERS reports that mention VIGABATRIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include SEIZURE, DRUG INEFFECTIVE, DRUG DOSE OMISSION, DEATH, SOMNOLENCE, PNEUMONIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Lundbeck Pharmaceuticals LLC in connection with VIGABATRIN. Always verify the specific product and NDC with your pharmacist.